Congresos

Interactive Monoaminergic Basis of Brain Disorders

Mojácar (Almería)

October 8 - 12 1997

The content of this congress, together with other contributions on the topic, are collected in vol. 4 of the series "Strategies for studying brain disorders".

PROGRAMME

• Tomás Palomo and Trevor Archer.
  The interactive essence underlying the dopamine disease states.

S1. DISORDERS OF ANXIETY, DEPRESSION AND SOCIAL BEHAVIOUR

• Gerald Curzon, U.K.
  Neurochemistry and drug treatment of depression and its implications.
• R. John Rodgers, U.K.
  Serotonin receptors and possible interactions in anxiety.
• Peter Nordström, Sweden.
  Survival analysis and psychobiology of suicide risk.
• Victor Pérez-Sola, Spain.
  Receptor interactions in clinical delayed response.
• Herman Van Praag, The Netherlands.
  Is depression a mood disorder?.
• Philipp Cowen, U.K.
  Serotonin in the pathophysiology of depression and the action of antidepressant drugs.

S2. SUBSTANCE ABUSE AND RELATED DISORDERS

• Jack Henningfield, USA.
  Pathophysiology of nicotine dependence: Implications for the regulation of cigarettes and treatment of nicotine dependence.
• Robert Balster, USA.
  Interactions among monoaminergic and glutamatergic systems in the neural basis of substance abuse.
• Miguel Casas-Brugé, Spain.
  Effects of Naltrexone on the expression of environmental conditioned self-injurious behaviour in rats: Relevance in drug addictions.
• Michael W. Oglesby, USA.
  Tolerance to the subjective effects of CNRS stimulants.
• Jorgen Engel, Sweden.
  Neurochemical and behavioural studies on ethanol and nicotine interactions.

S3. SCHIZO-PSYCHOTIC DISORDERS

• Bita Moghaddam, USA.
  Neurochemical and behavioural studies of dopamine-glutamate interactions.
• Mark Geyer, USA.
  Multiple Transmitters Modulate Prepulse Inhibition: Relevance to Schizophrenia.
• Stevin H. Zorn, USA.
  Pharmacological and Neurochemical Studies with the new antipsychotic ziprasidone.
• Nicholas A. Moore, UK.
  Expected neuropharmacological profiles of novel antipsychotic agents.
• Torgny Svensson, Sweden.
  Stabilization of mesocorticolimbic dopamine systems in psicosis by concomitant 5-HT2A and α1 receptor blockade.
• Victor Peralta, Spain.
  Clinical models of squizophrenia: A critical approach to competing conceptions.
• Anna-Lena Nordström, Sweden.
  Neuroimaging profiles of D2-5HT2 receptors.

S4. MOVEMENT DISORDERS

• Ulrich Ebert, Germany.
  Monoamine interactions in animal models of epilepsy.
• Trevor Archer, Sweden.
  Functional effects of acute and chronic L-dopa upon hypokinesive MPTP mice: Glutamate antagonists and inhibitors of MAO/COMT.
• Pierre Sokoloff, France.
  Functional and therapeutic implications of D1/D3 receptor interactions.
• Werner J. Schmidt, Germany.
  Monoamine-glutamate interactions in motor activity and learning.
• Erik Claveria, Spain.
  Treatment profiles of compounds useful for the movement disorders.
• Thomas N. Chase, USA.
  Striatal dopaminergic-glutamatergic interactions: Contribution to response alterations to levodopa in advanced Parkinson’s disease.

S5. NEUROPHARMACOLOGY OF DRUG-RECEPTOR ACTIONS.

• Richard J. Beninger, Canada.
  Dopamine-second messenger interactions in reward-related learning.
• David Jackson, Sweden.
  Nitric oxide synthase (NOS), phencyclide (PCP)-induced behaviours and schizophrenia
• David Sanger, France.
  Using drugs discrimination in rats to investigate the pharmacology of Dopamine D3 receptors.
• Jorge Manzanares, Spain.
  New agonists and antagonist of 5-HT1A receptor as potential tools in neuropsychiatric disorders.
• Robert Dantzer, France.
  Neuroimmune interactions and brain disorders.

S6. GENERAL CONSIDERATIONS DRUG-RECEPTOR INTERACTIONS IN BRAIN DISORDERS

• Alain Schotte, Belgium.
  Functional correlates of neurotransmitter receptor occupancy by antipsychotic drugs in the rat brain: the induction of neurotensin mRNA.
• Ivan Izquierdo, Brasil.
  Brain neurotransmitter interactions: The model case of memory processing.
• Peter Kalivas, USA.
  Drug-and stress-induced psychotic behaviours implying multisystems.
• Anna Sluzewska, Poland.
  Immunologic factors in major depression and treatment resistant depression.
• Tomás Palomo, Spain.
  Interactive Monoaminergic Basis of Brain Disorders.